Efficacy of a travelers' diarrhea vaccine system in travelers to India

Journal of Travel Medicine

Volumn 20, Issue 6, 2013, Pages 374-379

  Steffen, Robert ^a   Cramer, Jakob P ^b,c   Burchard, Gerd ^b,c   Jelinek, Tomas ^d   Schwarz, Ute ^d   Ramdas, Prabhugaunker ^e   Chatterjee, Santanu ^f   Jiang, Zhi Dong ^g   Dupont, Herbert L ^g   Dewasthaly, Shailesh ^h   Westritschnig, Kerstin ^h   Behrens, Ronald H ⁱ  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^d Berlin Center for Travel and Tropical Medicine   (Germany)

^e Prabhugaunker's Clinic   (India)

^f Wellesley Medicentre   (India)

^g UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^h INTERCELL AG   (Austria)

ⁱ HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROTOXIGENIC ESCHERICHIA COLI LABILE TOXIN VACCINE; PLACEBO; UNCLASSIFIED DRUG; VACCINE;

ADULT; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENTEROTOXIGENIC ESCHERICHIA COLI; ERYTHEMA; FEMALE; HUMAN; HYPERPIGMENTATION; IMMUNOGENICITY; INCIDENCE; INDIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL PATCH; TRAVELLER DIARRHEA; VACCINATION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; BACTERIAL VACCINES; DIARRHEA; DOUBLE-BLIND METHOD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GERMANY; GREAT BRITAIN; HUMANS; INCIDENCE; INDIA; MALE; MIDDLE AGED; TRAVEL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886949760     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/jtm.12064     Document Type: Article

References (12)

1. Steffen R,. Epidemiology of traveler's diarrhea. Clin Infect Dis 2005; 41 (Suppl 8): S536-S540.
2. Pitzurra R, Fried M, Rogler G, et al. Irritable bowel syndrome among a cohort of European travelers to resource-limited destinations. J Travel Med 2011; 18: 250-256.
3. Jiang ZD, DuPont HL, Brown EL, et al. Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter species. J Clin Microbiol 2010; 48: 1417-1419.
4. Isidean SD, Riddle MS, Savarino SJ, Porter CK,. A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. Vaccine 2011; 29: 6167-6178.
5. Peltola H, Siitonen A, Kyrönseppä H, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991; 338: 1285-1289.
6. Glenn GM, Rao M, Matyas GR, Alving CR,. Skin immunization made possible by cholera toxin. Nature 1998; 391: 851.
7. Glenn GM, Scharton-Kersten T, Vassell R, et al. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 1999; 67: 1100-1106.
8. Scharton-Kersten T, Glenn GM, Vassell R, et al. Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine 1999; 17 (Suppl 2): S37-S43.
9. Scharton-Kersten T, Yu J, Vassell R, et al. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 2000; 68: 5306-5313.
10. Frech SA, DuPont HL, Bourgeois AL, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008; 371: 2019-2025.
11. Behrens RH, Cramer JP, Jelinek T, et al. Efficacy and safety of a patch vaccine against traveller's diarrhoea: a randomized, double-blind, placebo-controlled phase III trial in travellers to Mexico and Guatemala. Lancet Infect Dis 2013. (In press).
12. Jiang ZD, Lowe B, Verenkar MP, et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 2002; 185: 497-502.